
New Diabetes Technology: Fact and Fantasy
Home / Resources / Articles / New Diabetes Technology: Fact and Fantasy
New Diabetes Technology: Fact and Fantasy
Guest Post by David Kliff, Diabetic Investor
Diabetes technology is evolving in a very exciting way, said Jeff Dachis, CEO and Founder of One Drop. But not surprisingly for the vast majority of people with diabetes worldwide, expensive sensors, automated insulin delivery solutions, or call center approaches to care can create barriers and challenges to effective disease management. This statement came from a MannKind press release announcing a new clinical trial.
Appropriate people with type 2 diabetes who meet inclusion criteria will be randomized to one of two treatment arms: Afrezza with One Drop | Premium or One Drop | Premium alone. Changes in hemoglobin A1C, quality of life, self-care, treatment satisfaction, and other metrics will be assessed.
Now before we get into whats really going on here I have a few quick thoughts about this trial. First, it is refreshing to see One Drop participate in a real randomized controlled clinical trial, as they have tended to use self-reported data to prove their system works. Two, I suspect that when this trial is over both groups will show various levels of improvements in HbA1c. As I keep saying Afrezza does work; this has never been in dispute. The problems with Afrezza have nothing to do with whether it works. Third, the results of this trial will do nothing to change the fortunes of MannKind or One Drop.
What I found interesting was Mr. Dachis choice of words, as he has drawn a line in the sand. Expensive
Continue
reading